Setmelanotide
Combined Pituitary Hormone Deficiencies, Genetic Form
Explore 1 assets in Combined Pituitary Hormone Deficiencies, Genetic Form →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Rhythm Pharmaceuticals, Inc.
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06760546CT.gov A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Combined Pituitary Hormone Deficiencies, Genetic Form
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Setmelanotide (this asset) | Rhythm Pharmaceuticals, Inc. | P3 | B · 60 |
Other indications for Setmelanotide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bardet-Biedl Syndrome | — | P4 | A · 81 |
| Alstrom Syndrome | — | P4 | BBB · 75 |
| Inherited Obesity | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Setmelanotide in Combined Pituitary Hormone Deficiencies, Genetic Form. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/setmelanotide-combined-pituitary-hormone-deficiencies-genetic-form
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →